Date: 13th August, 2026

To,
General Manager-Listing,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Subject: Statement of Deviation or Variation under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended 30th June,2026

Script Code - 527005; ISIN - INE847D01010

Dear Sir/Ma'am,

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/ CFD/ CMD1/162/2019 dated December 24, 2019, a statement confirming that there is no deviation(s) or variation(s) in utilization of funds raised through Preferential Issue for the quarter ended 30th June, 2026. The said statement was reviewed by the Audit Committee and taken on record by the Board.

You are requested to please take the same on record.

Thanking You

Yours faithfully
FOR SHREE PACETRONIX LIMITED
CIN- L33112MP1988PLC004317

RUPALI AHIRE
Digitally signed by RUPALI AHIRE
Date: 2026.08.13 17:08:39 +05'30'

SHREE PACETRONIX LTD.

RUPALI AHIRE
COMPANY SECRETARY

Annexure-A

STATEMENT OF DEVIATION/ VARIATION IN UTILIZATION OF FUND RAISED

<table>
<tr><td>Name of the Listed Entity</td><td>Shree Pacetronix Limited</td></tr>
<tr><td>Mode of Fund Raising</td><td>Allotment of Equity share and warrants on a Preferential basis</td></tr>
<tr><td>Date of Raising Fund</td><td>
<table>
<tr><td>Particulars</td><td>Date of Allotment</td><td>No. of Equity Shares and Warrants</td><td>Money Received on Allotment</td></tr>
<tr><td>Equity Share</td><td>14.11.2025</td><td>75150</td><td>Rs. 60,87,150/-</td></tr>
<tr><td>Warrants (Series A)</td><td>14.11.2025</td><td>75150</td><td>Rs. 15,21,787.5/- (Upfront receipt of 25% of total consideration)</td></tr>
<tr><td>Warrants (Series A) Equity Shares pursuant to conversion of warrants</td><td>20.03.2026</td><td>75150</td><td>Rs. 45,65,362.50/- (75% received at the time of conversion)</td></tr>
<tr><td>Warrants (Series B)</td><td>14.11.2025</td><td>150300</td><td>Rs. 30,43,575/ (Upfront receipt of 25% of total consideration) received at the time of conversion)</td></tr>
</table>
</td></tr>
<tr><td>Amount Raised (Rs. In Lakh)</td><td>Total Amount Raised Rs. 243.48/- out of which Rs. 152.18/- received at the time of allotment</td></tr>
<tr><td>Report filed for Quarter Ended</td><td>30th June, 2026</td></tr>
<tr><td>Monitoring Agency</td><td>Not Applicable</td></tr>
<tr><td>Monitoring Agency Name, If Applicable</td><td>Not Applicable</td></tr>
<tr><td>Is there a Deviation/ Variation in use of funds raised</td><td>No</td></tr>
<tr><td>If yes, whether the same in pursuant to change in terms of a contract or objects, which was approved by the</td><td>Not Applicable</td></tr>
<tr><td>If Yes, Date of shareholder Approval</td><td>Not Applicable</td></tr>
<tr><td>Explanation for the Deviation/Variation</td><td>Not Applicable</td></tr>
<tr><td>Comments of the Audit Committee after review</td><td>None</td></tr>
<tr><td>Comments of the Auditor, if any</td><td>None</td></tr>
</table>

OBJECT FOR WHICH FUND HAVE BEEN RAISED AND WHERE THERE HAS BEEN A DEVIATION, IN THE FOLLOWING TABLE:

Original Object	Modified Object, if any	Original Allocation (Rs. In Lakh)	Modified allocation, if any	Fund Utilised (Rs. In Lakh)	Amount of Deviation/Variation for the quarter according to the applicable object	Remarks, if any
(1) Capital Expenditure for setting up/upgrading manufacturing facilities for pacemaker production including automation and adoption of cleanroom technology (2)General Corporate purpose	NA	**(a)Original Allocation Amount:** (1) Allotment of Equity: 75150*81= Rs. 60.87 Lacs (2) Allotment of Warrants: 225450*81=Rs.182.61 Lacs **(b) Subscription received:** (1) Allotment of Equity: 75150*81=Rs. 60.87 Lacs (2) Allotment of warrants = 225450*20.25=Rs. 45.65 Lacs (Received 25% from the original allocation amount) (3) Allotment of Equity Share pursuant to the conversion of warrants:75150*60.75=45.65 Lacs (Received 75% from the original allocation amount)	Nil	21.55 0.74	Nil	*Refer Note
Total		152.18		22.29		

*Pursuant to the Board approval dated 14th November 2025, the Company allotted 75,150 fully paid-up equity shares of ₹81 each for an aggregate consideration of ₹60,87,150, against which the full amount was received.

Further, on the same date, the Company allotted 2,25,450 convertible warrants, comprising 75,150 Series A Warrants and 1,50,300 Series B Warrants, and received ₹45,65,362.50, being 25% of the warrant issue price as upfront consideration.

Subsequently, on 20th March 2026, 75,150 Series A Warrants were converted into fully paid-up equity shares, against receipt of the balance consideration of ₹45,65,362.50. The 1,50,300 Series B Warrants remained outstanding, subject to the terms of the issue and applicable regulatory provisions.

The warrants are valid for a specified period as per SEBI ICDR regulations, and holders may exercise their right to convert the warrants into equity shares within this period.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the fund have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

FOR SHREE PACETRONIX LIMITED
CIN- L33112MP1988PLC004317

RUPALI AHIRE
Digitally signed by RUPALI AHIRE
Date: 2026.08.13 17:09:53 +05'30'

RUPALI AHIRE
COMPANY SECRETARY